NCT05697809View on ClinicalTrials.gov

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Diabetic Macular Edema
Interventions
DRUG

OXU-001

Suprachoroidal sustained release dexamethasone acetate

DEVICE

Semi-automated suprachoroidal illuminated microcatheter

Ophthalmic administration device

DRUG

Ozurdex® Ophthalmic Intravitreal Implant

Ophthalmic dexamethasone intravitreal implant

Trial Locations (9)

33761

Blue Ocean Clinical Research West, Clearwater

55337

Retina Consultants of Minnesota, Minneapolis

60452

University Retina and Macula Associates, Oak Forest

77380

Retina Consultants of Texas, Houston

78240

Retinal Consultants of Texas - San Antonio, San Antonio

78503

Valley Retina Institute, PA, McAllen

85053

Retinal Research Institute, LLC, Phoenix

89502

Sierra Eye Associates, Reno

00612

Emmanuelli Research and Development Center, LLC, Arecibo

All Listed Sponsors
lead

Oxular Limited

INDUSTRY